London, Feb 1, 2026, 08:17 GMT — The market has closed.
- GSK shares ended Friday at 1,876.5 pence, gaining 1.3%.
- Investors are gearing up ahead of the company’s full-year and Q4 results, set for release on Feb. 4.
- Sterling swings and buzz around big pharma deals are shaping the outlook for the week ahead.
GSK shares closed Friday 1.32% higher at 1,876.50 pence, marking a steadier start to the month following a volatile January. As London markets remained closed over the weekend, focus now turns to upcoming earnings reports and the tone set by management. (Marketscreener)
The company plans to release its fourth-quarter results at 07:00 GMT on Wednesday, Feb. 4. A webcast will follow at 11:00 GMT, featuring Luke Miels and other executives. This sets a firm schedule for the stock’s next move. (Gsk)
The timing is key as the wider London market has been driven more by currency shifts and sector rotation than strong growth bets. The FTSE 100 rose 0.5% on Friday, marking its seventh consecutive month of gains. At the same time, the pound weakened against the dollar—a dynamic that typically boosts multinational earnings. “The weaker pound is obviously beneficial for the multinationals,” said Fiona Cincotta of City Index. (Reuters)
On Friday, GSK shares fluctuated between 1,833.00 and 1,879.00 pence, with roughly 8.9 million shares traded, according to London Stock Exchange data. That’s a decent volume heading into the weekend—not scarce, but far from a buying frenzy. (Londonstockexchange)
Broker forecasts gathered by GSK, effective Jan. 20, peg fourth-quarter “core” turnover— the company’s adjusted figure excluding some one-offs—at around 8.5 billion pounds. The consensus also points to core earnings per share (EPS) near 23 pence. Investors are zeroing in on sales of Shingrix and Arexvy vaccines, alongside HIV treatments like Dovato and Cabenuva. (Gsk)
Peers are active, helping sustain deal valuations and pipeline options in the market. AstraZeneca announced a licensing agreement with CSPC Pharmaceutical Group for experimental obesity drugs, involving $1.2 billion upfront and potential milestones hitting $17.3 billion. This move underscores big pharma’s ongoing appetite for high-growth sectors. (Reuters)
GSK’s name popped up outside earnings and M&A news in global health this week. The END Fund announced a new three-year project aimed at tackling neglected tropical diseases, with GSK throwing its weight behind it. Solomon Zewdu, the CEO, called the effort “a powerful coalition for change.” It’s tough to gauge the financial impact from the outside, but it fits into GSK’s ongoing focus on access and partnerships. (Endfund)
Investors remain cautious about GSK’s pipeline investments and bolt-on acquisitions. Earlier this month, the company struck a $2.2 billion deal to acquire RAPT Therapeutics, gaining access to an experimental food-allergy treatment. Reuters noted this move as part of GSK’s push to generate growth ahead of looming patent expirations in its HIV portfolio. Chief scientist Tony Wood described the drug as aligned with GSK’s focus on “validated targets.” (Reuters)
Still, the stock could tumble fast if the Feb. 4 update delivers cautious guidance, signals increased spending, or reveals softer demand in major franchises. Currency swings add another layer of risk — a stronger sterling would weigh on reported overseas sales.
The next major trigger is the full-year and Q4 earnings, set for release at 07:00 GMT on Feb. 4, just ahead of the London session. Traders will factor this in when markets open on Monday. (Gsk)
